Form 6-K Polyrizon Ltd. For: Dec 08
Polyrizon Ltd. - Ordinary Shares (PLRZ)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
PLRZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLRZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLRZ alerts
High impacting Polyrizon Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PLRZ
News
- Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses [Yahoo! Finance]Yahoo! Finance
- Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold VirusesGlobeNewswire
- Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel ProgramGlobeNewswire
- Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal SprayGlobeNewswire
- From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal ProtectionGlobeNewswire
PLRZ
Sec Filings
- 12/19/25 - Form 6-K
- 12/12/25 - Form SCHEDULE
- 12/12/25 - Form SCHEDULE
- PLRZ's page on the SEC website